Fox, Douglas B. http://orcid.org/0000-0003-3678-927X
Ebright, Richard Y. http://orcid.org/0000-0001-8975-5810
Hong, Xin http://orcid.org/0000-0002-9671-0116
Russell, Hunter C.
Guo, Hongshan
LaSalle, Thomas J.
Wittner, Ben S. http://orcid.org/0000-0001-5657-9849
Poux, Nicolas
Vuille, Joanna A. http://orcid.org/0000-0001-7713-9543
Toner, Mehmet
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Boland, Genevieve M. http://orcid.org/0000-0002-7522-6173
Sen, Debattama R. http://orcid.org/0000-0002-0947-8284
Sullivan, Ryan J.
Maheswaran, Shyamala http://orcid.org/0000-0002-9356-1709
Haber, Daniel A. http://orcid.org/0000-0003-1378-6551
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32CA009216, 1F30CA232407-01, T32GM007753, T32GM007753, 5U01EB012493, 5P41EB002503, 2U01EB012493, RO1CA129933)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 25 August 2022
Accepted: 10 February 2023
First Online: 2 March 2023
Competing interests
: Massachusetts General Hospital (MGH) has applied for patents regarding the CTC-iChip technology and CTC detection signatures. M.T., D.A.H., and S.M. are founders of and own equity in TellBio, Inc., which is involved with CTC therapeutics and diagnostics. At this time, there has been no funding received or license given to TellBio, Inc. R.J.S. is an unpaid consultant to BMS and a paid consultant to Merck, Novartis, and Pfizer. N.H. is a founder and advisor for Related Sciences/Danger Bio. R.Y.E. has received consulting fees from Nextech Invest and nference Inc., which are not related to this work. T.J.L. has received consulting fees from Chemomab Therapeutics, which are not related to this work. The interests of these authors were reviewed and managed by MGH and Partners HealthCare in accordance with their conflict of interest policies. All other authors declare no competing interests.